+ Reply to Thread
Results 1 to 2 of 2

Thread: NILE Therapeutics price target

  1. #1
    Junior Member
    Join Date
    Jul 2009
    Location
    PARMA Italy
    Posts
    13
    Rep Power
    38

    Default NILE Therapeutics price target

    August 16, 2010

    Nile Therapeutics Reports 2010 Second Quarter Financial Results


    About Nile Therapeutics

    -- Nile Therapeutics, Inc. (NASDAQ: NLTX), a company focused on the development of novel therapeutics for heart failure patients today.......

    ..................


    Update on CD-NP

    During June 2010, Nile completed enrolling a placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure ("ADHF") in the United States, Germany and Israel. In total, 77 patients were randomized into four doses of CD-NP (1.25, 2.5, 3.75 and 5 ng/kg/min) vs. placebo. The last patient visit occurred at the end of July and final results from the study are expected in the fourth quarter of 2010. Also in the fourth quarter of 2010, Nile plans to submit to the FDA for review and discussion, the clinical protocol for a double-blind, placebo controlled Phase IIb study of CD-NP in ADHF patients.


    Nile Therapeutics, Inc.
    August 20, 2010
    NLTX

    Nile Therapeutics, Inc. (NLTX - Analyst Report) is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF).
    Prior phase I and phase II data so far has been highly encouraging. With a market capitalization of only $14 million, Nile Therapeutics shares are bafflingly under-valued.

    We believe with positive data from the ongoing phase II program in hand the company is worth at least $80 to 100 million. Taking the mid-range at $90 million, and then backing out the $20 million most likely required to fund the phase IIb program, we arrive at a value of $70 million for Nile Therapeutics. This equates to a price of $2.00 per share.


    This study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure


    Verified by Nile Therapeutics, March 2010
    First Received: February 6, 2009 Last Updated: March 5, 2010 History of Changes
    Sponsor: Nile Therapeutics
    Information provided by: Nile Therapeutics
    ClinicalTrials.gov Identifier: NCT00839007
    Purpose
    The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.


    Condition Intervention Phase
    Acute Decompensated Heart Failure
    Drug: CD-NP
    Phase II

    Official Title: A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

    Resource links provided by NLM:

    MedlinePlus related topics: Heart Failure
    U.S. FDA Resources

    Further study details as provided by Nile Therapeutics:

    Primary Outcome Measures:
    The occurence of hypotensive events, clinical symptoms, and renal function change with CD-NP infusion. [ Time Frame: Up to 72 hours ] [ Designated as safety issue: Yes ]

    Estimated Enrollment: 75
    Study Start Date: June 2009
    Estimated Study Completion Date: September 2010
    Estimated Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)


    Make your considerations ...
    Now the price is 0.62

    Last edited by giasone; 10-08-2010 at 06:31 AM. Reason: correction

  2. #2
    Junior Member
    Join Date
    Jul 2009
    Location
    PARMA Italy
    Posts
    13
    Rep Power
    38

    Default

    Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board

    SAN MATEO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that Michael R. Bristow, M.D. Ph.D. has joined the Scientific Advisory Board overseeing the development of CD-NP, a dual natriuretic peptide receptor agonist in development for the treatment of acute decompensated heart failure.
    Dr. Bristow, a recognized leader in the heart failure community, is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was a founder of ARCA biopharma, a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. Dr. Bristow currently serves as Director, President and Chief Executive Officer of ARCA biopharma. Dr. Bristow was the principal founder of Myogen, biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for the treatment of cardiovascular and pulmonary disease. Dr. Bristow served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow is also a founder of Miragen Therapeutics, a Boulder, CO based microRNA company.
    "We are extremely pleased to welcome Dr. Bristow to our advisory board," said Joshua A. Kazam, Nile's CEO. "We believe that his depth of knowledge in the field of heart failure and his breadth of experience in drug development and commercialization will help us achieve the full potential of CD-NP and our natriuretic peptide program."


    NILE IS ON THE MOVE...+ 20% but it's steel very cheap !!!

+ Reply to Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts